Citius Pharmaceuticals stock heads into Jefferies London conference

Citius Pharmaceuticals said on November 11 that Chairman and CEO Leonard Mazur will participate in the Jefferies London Healthcare Conference from November 16 to 19. According to the WFMZ report carrying the PR Newswire release, Mazur will provide an overview of the business and recent developments while holding one-on-one business development meetings.

Citius Pharmaceuticals stock traded at 0.48 US dollars on Nasdaq in after-hours trading at 22:00 CET on Wednesday, November 11. No Xetra comparison is included because the available quote is a Nasdaq dollar-denominated after-hours price.

Commercial Focus Stays On LYMPHIR

The conference presentation is expected to focus on the ongoing commercialization of LYMPHIR by majority-owned Citius Oncology. The targeted immunotherapy was launched in December 2025 for adults with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy.

Citius has also identified Mino-Lok, a catheter lock solution for catheter-related bloodstream infections, and CITI-002, known as Halo-Lido, as late-stage programs. The company said it remains engaged with the U.S. Food and Drug Administration on next steps for those programs.

Company And Competitive Position

Citius Pharmaceuticals is a U.S. biopharmaceutical company focused on developing and commercializing critical-care products, with oncology, anti-infective support and specialty prescription products in its portfolio. Its majority-owned Citius Oncology unit provides the commercial oncology platform around LYMPHIR. The company operates in a CTCL field that also includes larger oncology groups such as Kyowa Kirin, Pfizer's Seagen unit and Takeda, while Citius remains focused on a narrower portfolio of targeted products.

Broader trading conditions can be followed through the S&P 500 market environment.

More news and analyses on Citius Pharmaceuticals stock.